SecurityROSE / Rosehill Resources Inc. (777385105)
Common Shares Outstanding229,807,692 shares (as of 2018-03-31)
Total Insiders32
Total Directors7
Total Officers5

Stock Insider Trading (from SEC Form 4)

Rosehill Resources Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ROSE / Rosehill Resources Inc. insiders include WAM GP LLC, KLR Energy Sponsor, LLC, WEISS ANDREW M, Owen Robert Craig, AIO V AIV 3 Holdings, L.P., and Tema Oil & Gas Co, Shawn Kimel Investments, Inc., Anchorage Illiquid Opportunities V, L.P. Rosemore Holdings, Inc., Kimel Shawn, Ayers Brian K., HANNA GARY C, Townsend James Alan, Kovalik Edward, Buerger Reid S, Thom Tiffany J, K2 GENPAR LP, ROSEMORE, INC., Quarls Harry, Anchorage Capital Group, L.L.C., K2 GENPAR 2009 INC, K2 PRINCIPAL FUND, L.P., MAYER WILLIAM E, Rosenberg Frank, CONTINO FRANCIS A, Williford Robert Colby, K2 & Associates Investment Management Inc., Anchorage Advisors Management, LLC, Weiss Asset Management LP, Polar Asset Management Partners Inc., Geode Capital Master Fund Ltd. - Geode Diversified Fund, Ulrich Kevin Michael, .

Insider Roster

Insider Dir Off 10% Shares Owned
K2 & Associates Investment Management Inc. 10% Owner
K2 GENPAR LP 10% Owner
Shawn Kimel Investments, Inc. 10% Owner
K2 GENPAR 2009 INC 10% Owner
Kimel Shawn 10% Owner
K2 PRINCIPAL FUND, L.P. 10% Owner
X 321,724
Quarls Harry Director
X 56,489
Shawn Kimel Investments, Inc. 10% Owner
K2 GENPAR 2009 INC 10% Owner
K2 GENPAR LP 10% Owner
Kimel Shawn 10% Owner
K2 & Associates Investment Management Inc. 10% Owner
K2 PRINCIPAL FUND, L.P. 10% Owner
X 338,324
MAYER WILLIAM E Director
X 36,671
CONTINO FRANCIS A Director
X 46,671
Rosenberg Frank Director
X 36,671
HANNA GARY C Director
X 212,784
Kovalik Edward Director, 10% Owner
X X 1,377,292
K2 GENPAR 2009 INC 10% Owner
Kimel Shawn 10% Owner
K2 GENPAR LP 10% Owner
K2 PRINCIPAL FUND, L.P. 10% Owner
K2 & Associates Investment Management Inc. 10% Owner
Shawn Kimel Investments, Inc. 10% Owner
X 346,724
Owen Robert Craig Chief Financial Officer
X 281,728
Williford Robert Colby Vice President of Land
X 80,867
Kimel Shawn 10% Owner
K2 & Associates Investment Management Inc. 10% Owner
Shawn Kimel Investments, Inc. 10% Owner
K2 GENPAR 2009 INC 10% Owner
K2 PRINCIPAL FUND, L.P. 10% Owner
K2 GENPAR LP 10% Owner
X 407,382
Ayers Brian K. Vice President of Geology
X 110,555
Townsend James Alan See Remarks, Director
X X 336,126
Geode Capital Master Fund Ltd. - Geode Diversified Fund 10% Owner
X 674,214
Rosemore Holdings, Inc. 10% Owner
X
Tema Oil & Gas Co 10% Owner
ROSEMORE, INC. 10% Owner
X
Buerger Reid S 10% Owner
X 1,673,570
K2 GENPAR LP 10% Owner
Kimel Shawn 10% Owner
K2 PRINCIPAL FUND, L.P. 10% Owner
K2 & Associates Investment Management Inc. 10% Owner
Shawn Kimel Investments, Inc. 10% Owner
K2 GENPAR 2009 INC 10% Owner
X 1,063,302
Anchorage Advisors Management, LLC 10% Owner
Anchorage Capital Group, L.L.C. 10% Owner
Ulrich Kevin Michael 10% Owner
AIO V AIV 3 Holdings, L.P. 10% Owner
Anchorage Illiquid Opportunities V, L.P. 10% Owner
X 612,876
ROSEMORE, INC. 10% Owner
Rosemore Holdings, Inc. 10% Owner
Tema Oil & Gas Co 10% Owner
X
Thom Tiffany J CHIEF FINANCIAL OFFICER
X 140,000
Polar Asset Management Partners Inc. 10% Owner
X
Weiss Asset Management LP 10% Owner
WAM GP LLC 10% Owner
WEISS ANDREW M 10% Owner
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-22 4 K2 PRINCIPAL FUND, L.P. S D 8.2352 -16,600 321,724 2,649,461
2018-05-21 4 Quarls Harry P D 8.02 2,600 56,489 453,042
2018-05-18 4 Quarls Harry P D 8.05 700 53,889 433,806
2018-05-17 4 Quarls Harry P D 8.15 6,700 53,189 433,490
2018-05-17 4 K2 PRINCIPAL FUND, L.P. S D 8.2 -8,300 338,324 2,774,257
2018-05-16 4 K2 PRINCIPAL FUND, L.P. S D 8.225 -100 346,624 2,850,982
2018-05-11 4 Kovalik Edward A D 19,060 1,377,292
2018-05-11 4 HANNA GARY C A D 19,060 212,784
2018-05-11 4 Rosenberg Frank A D 19,060 36,671
2018-05-11 4 Quarls Harry A D 19,060 46,489
2018-05-11 4 CONTINO FRANCIS A A D 19,060 46,671
2018-05-11 4 MAYER WILLIAM E A D 19,060 36,671
2018-05-09 4 K2 PRINCIPAL FUND, L.P. S D 7.9126 -1,900 346,724 2,743,488
2018-05-07 4 K2 PRINCIPAL FUND, L.P. S D 7.9872 -7,357 348,624 2,784,530
2018-04-27 4 Williford Robert Colby F D 7.95 -4,211 80,867
2018-04-27 4 Owen Robert Craig F D 7.95 -14,701 281,728
2018-04-26 4 K2 PRINCIPAL FUND, L.P. S D 8.0372 -50,000 355,981 2,861,090
2018-04-25 4 K2 PRINCIPAL FUND, L.P. S D 8.2 -1,401 405,981 3,329,044
2018-04-24 4 K2 PRINCIPAL FUND, L.P. S D 8.0082 -11,583 407,382 3,262,397
2018-04-23 4 K2 PRINCIPAL FUND, L.P. S D 8.0752 -8,505 418,965 3,383,226
2018-04-19 4 K2 PRINCIPAL FUND, L.P. S D 7.5584 -7,564 427,470 3,230,989
2018-04-13 4 K2 PRINCIPAL FUND, L.P. S D 6.8624 -25,581 435,034 2,985,377
2018-03-26 4 Owen Robert Craig A D 115,296 296,429
2018-03-26 4 Townsend James Alan A D 139,946 336,126
2018-03-26 4 Williford Robert Colby A D 33,191 85,078
2018-03-26 4 Ayers Brian K. A D 39,014 110,555
2018-03-12 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 6.0822 -11,400 674,214 4,100,704
2018-03-09 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 6.0863 -611 685,614 4,172,852
2018-03-08 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 6.2245 -4,506 686,225 4,271,408
2018-03-07 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 6.2878 -2,515 690,731 4,343,178
2018-02-28 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 6.2409 -10,300 693,246 4,326,479
2018-02-26 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 7.0169 -7,900 703,546 4,936,712
2018-02-15 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 7.5138 -3,574 711,446 5,345,663
2018-02-08 4 K2 PRINCIPAL FUND, L.P. P D 6.3861 3,500 460,615 2,941,533
2017-12-22 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund C D 11.5 43,478 699,020
2017-12-20 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.2032 -60,500 699,020 5,734,201
2017-12-19 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.4851 -920 759,520 6,444,603
2017-12-18 4 Townsend James Alan A D 8.615 2,500 196,180
2017-12-18 4 Quarls Harry P D 8.55 2,320 27,429 234,518
2017-12-15 4 Quarls Harry P D 8.43 2,680 25,109 211,669
2017-12-18 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.5224 -5,500 760,441 6,480,782
2017-12-15 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.4361 -1,525 765,941 6,461,555
2017-12-14 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.3861 -3,700 767,466 6,436,047
2017-12-14 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund C D 11.50 43,478 771,166
2017-12-13 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.9897 -7,593 771,166 6,932,551
2017-12-12 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.9762 -1,472 778,759 6,990,297
2017-12-11 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.9753 -5,156 780,231 7,002,807
2017-12-05 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 8.937 -409 785,387 7,019,004
2017-12-04 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 9.0075 -1,400 785,796 7,078,057
2017-12-01 4 Geode Capital Master Fund Ltd. - Geode Diversified Fund S D 9.1451 -3,298 787,196 7,198,986
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Rosehill Resources' (ROSE) CEO Alan Townsend on Q1 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good day, ladies and gentlemen and welcome to the Rosehill Resources' First Quarter 2018 Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's program maybe recorded. (1-0)

Fifth Third's (FITB) Q1 Earnings & Revenues Beat Estimates

2018-04-24 zacks
Have you been eager to see how Fifth Third Bancorp (FITB - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this Ohio-based bank’s earnings release this morning: An Earnings Beat Fifth Third came out with adjusted earnings per share of 57 cents, surpassing the Zacks Consensus Estimate of 48 cents. The figure excludes the net positive impact of gain from the Vantiv merger with WorldPay and charges related to the valuation of the Visa total return swap and adjustment to litigation reserves. (72-0)

Can The Uptrend Continue for Rosehill Resources (ROSE)?

2018-04-23 zacks
Investors certainly have to be happy with Rosehill Resources Inc. (ROSE - Free Report) and its short term performance. After all, the stock has jumped by 23.3% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for ROSE? (8-0)

Construct Your Oil Portfolio: The Capital Appreciation Version

2018-04-23 seekingalpha
This is Part 3 of a three-piece series aiming to take a long, hard look at how to go about building an oil stock portfolio that fits your personality. (20-1)